Distribution and Determinants of Colon Cancer Risk, Survivorship and Outcomes

Fat Absorption & Colon Cancer

Fat absorption may play a critical role in colorectal carcinogenesis by determining intra-colonic exposure to carcinogens. In a large case-control study, the association between colon cancer risk and genetic variation in FABP2 and APOE was evaluated. The analysis found a negative gene x environment interaction between the FABP2 codon 54 polymorphism and fat intake in determining colorectal cancer risk. The controls from this study were used to evaluate expression of resistin-like molecules (RELM) that play a role, in animal models, in insulin resistance and intestinal inflammation. Program members demonstrated the presence of RELMβ in the plasma, with lower levels in sub-populations of non-whites, lower pack-years of cigarette smoking, and higher physical activity index levels.  The direct association between RELMβ with smoking and physical activity, both of which are risk factors for colorectal cancer, suggests that RELMβ may be involved mediating the effects of these modifiable risk factors. The large case-control study also reported that the protective effects of quercetin intake, as measured by a food frequency questionnaire, were confined to proximal colon cancer and specifically when fruit intake or the Health Eating Index was high, or when tea intake was low.  Conversely, for distal colon cancer, increased quercetin intake was associated with increased risk when total fruit intake is low. Smoking and diets high in red meat, both associated with colon cancer risk, may increase iron exposure, favoring colonization of certain bacterial pathogens. Program members reported an increased risk of colorectal cancer when there are exposures to both heme iron intake and pack-years, with some suggestion that antibodies against flagelin of Salmonella increased risk even further.  Research for diet-microbial interactions is now planned.  Program members also discovered several novel variants in Helicobacter pylori cytotoxin-associated genes and will verify these results in a bigger sample.

  • Lead Researchers: Dr. Kato
  • Grant: R01 CA093817

Women & Colorectal Cancer

Women Health Initiative studies lead by a program member included findings of a reduction in race-related colorectal cancer incidence between African American and white women once sociodemographic factors are considered, a reduced risk of colorectal cancer in women taking lovastatins, and a reduced risk in women taking combined hormone therapy (HR=0.72, 95% CI 0.56-0.94), however those women in the treatment group had colorectal cancers that more commonly presented with positive lymph nodes and higher stage (Simon, J Clin Oncol, 2012).  

  • Lead Researcher: Dr. Simon

Intervention Research with African Americans to Reduce and Eliminate Disparities

Colorectal Cancer

Although African Americans are at an increased risk of developing and dying from colorectal cancer (CRC), many efforts to encourage early detection have been unsuccessful. The long-term goal of this research is to develop cost-effective public health messages that reduce health disparities, and to examine psychological processes that serve as mechanisms explaining effective health messaging with African Americans. Program members are testing the effects of an intervention using unique versions of a CRC informational and screening video messaging system. The aims are to 1) identify and compare effects of stand-alone gain versus loss-framed health messages on African-Americans' CRC screening attitudes, intentions, and behavior; 2) identify and compare effects of gain versus loss-framed health messaging on African-Americans' perceived racism and medical mistrust; and 3) determine the effect of coupling gain and loss-framed messages with culturally-targeted personal prevention messages on African-Americans' CRC screening attitudes, intentions, and behavior.

  • Lead Researcher: Dr. Lucas
    Grant: R01 CA175088

The Latest From Karmanos Cancer Institute

News

IN THE NEWS: Detroit Cancer Center Unveils New Device for Treating Liver Cancer at Home

The Detroit News The TheraBionic P1 device is now available for patients who have advanced liver cancer and have failed first- and second-line the...

Read More

Karmanos Cancer Institute Physicians Begin Prescribing New FDA-approved Radiofrequency Electromagnetic Device to Treat Advanced Liver Cancer

The Barbara Ann Karmanos Cancer Institute , the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announce...

Read More

CURE, in Collaboration with Karmanos' Office of Cancer Health Equity and Community Engagement, Educates the Community About Metastatic Breast Cancer

On Wednesday, Dec. 4, 2024, patients, survivors, and advocates gathered at Karmanos Cancer Institute in Detroit to learn about metastatic breast c...

Read More
News

WDET | Scholarship Program Aims to Encourage More Diversity in Clinical Trials

Listen Now

101 WRIF | Lung Cancer Awareness

Listen Now

Becker’s Healthcare Podcast | Exploring Breakthroughs in Cancer Treatment with Dr. Boris C. Pasche, President & CEO at Karmanos Cancer Institute

Listen Now